Table 1 Assignment of each cynomolgus macaque to low dose (1 infected mosquito) or high dose (10 infected mosquitoes) of DENV, or high dose (15 infected mosquitoes) of ZIKV, or control (10 uninfected mosquitoes) treatments and subsequent viremia, transmission to mosquitoes, and neutralizing antibody response

From: Trade-offs shaping transmission of sylvatic dengue and Zika viruses in monkey hosts

NHP ID

Sex

A priori Virus treatment

Post hoc Virus Treatmenta

No. infected mosquitoes engorged

No. infected mosquitoes with detectable virus in saliva post passageb; (total dose virus delivered (log10 pfu))c

Days on which virus was detectable in serum, day of peak titer (peak titer log10pfu/ ml)

Days on which virus was transmitted to mosquitoes (% infectedd)

PRNT80 on Day

−10

28

NV289

M

Control

Control

8

0

<20

<20

UG171

F

Control

Control

5

0

<20

<20

NV259

F

Control

Control

9

0

<20

<20

SB393

M

Low Dose DENV

Low Dose DENV

1

0

<20

40

FR469A

M

Low Dose DENV

Low Dose DENV

1

1

4 (3.9)

<20

160

UG253Aa

M

Low Dose DENV

Control

1

0

<20

<20

BC407

F

Low Dose DENV

Low Dose DENV

1

1

<20

<20

CP60

F

Low Dose DENV

Low Dose DENV

1

1

<20

80

BC116A

M

High Dose DENV

High Dose DENV

7

6

4 (nae)

<20

40

FR423A

M

High Dose DENV

High Dose DENV

8

5

4, 7 (2.5)

5 (60%)

<20

320

SB395

F

High Dose DENV

High Dose DENV

8

3

<20

1280

FR840

F

High Dose DENV

High Dose DENV

9

4

8 (100%)

<20

320

BC167

F

High Dose DENV

High Dose DENV

7

3

5 (20%)

<20

1280

UGZ626

F

High Dose ZIKV

High Dose ZIKV

7

7

(4.41)

2, 3, 4, 5 (5.0)

2 (40%)

3 (54%)

4 (89%)

5 (70%)

<20

>640

EC644

M

High Dose ZIKV

High Dose ZIKV

11

9

(4.48)

3, 4, 5 (5.3)

3 (30%)

4 (100%)

5 (100%)

<20

160

FR1221

F

High Dose ZIKV

High Dose ZIKV

7

5(4.42)

3, 4, 5 (4.7)

3 (9%)

4 (81%)

5 (100%)

<20

40

  1. aSee text for justification of change from a priori to post hoc assignment.
  2. bIncludes only mosquitoes that survived the two-day rest period post-feeding. Survival was generally very high; survival data is available in Supplementary Datasets 1 and 3.
  3. cZIKV only; since viremia was never detected from unpassaged saliva for DENV-2, number of engorged mosquitoes was used as a proxy for dose delivered.
  4. dConsidered positive if virus detected in bodies or legs, which were processed separately.
  5. eNot applicable as viremia was detected only post-passage.